Primary Packaging - Gx® prefillable syringes

Since 2015 Centor is a member of the Gerresheimer Group and the largest supplier of regulatory compliant prescription plastic containers for medication dispensing for the North American prescription retail market. The product portfolio includes the flagship products 1-Clic® vials and closure systems,...

Gx® RTF vials enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and tra...

The Gx Elite vials are the result of a careful product development process spanning several years. The highly shatter-resistant vials are extremely durable and free of cosmetic defects. They also boast an incredibly robust structure, while their resistance to delamination protects the drug inside. Simp...

Our tubular vials product range includes clear and amber vials in glass types I, II and III from 0.6 to 100 ml. We produce different designs, with or without blowback, according to industry standards or to individual specifications. As a special feature we offer sterile RTF® vials based on its long e...

Gerresheimer produces high-quality cartridges with fill volumes ranging from 1.5 to 3.0 ml (sizes up to 10.0 ml on request) for various pharmaceutical applications. Our product range covers clear and amber cartridges made of borosilicate glass of hydrolytic class I. Individual options, such as an a...

Gerresheimer offers a broad portfolio of highly competitive pharmaceutical ampoules in type I pharma glass. Our standard range covers ampoules made of flint and amber glass with filling capacities from 1 to 30 ml. These include straight-stem, funnel-type and closed ampoules of ISO types B, C and D ...

Biotech derived drug products are characterized by several specific requirements. Some are highly viscous and, in individual cases, tend to interact with silicone oil or, for example, tungsten residues from syringe production. Gerresheimer therefore offers the “metal-free” production avoiding the u...

One problem associated with syringe use is that traces of tungsten or other metals occasionally leave residue behind in the bore when the syringe cone is shaped. Gerresheimer developed a production technology registered for patent where the pin used to shape the cone is made of a special ceramic. So we can...

Gx RTF® ClearJect® syringes are made from COP (Cyclo Olefin Polymer). They are glue-free as the cannula is not glued in, but is instead insert-molded during the injection molding process, no aggregation due to metal or tungsten residues, high viscosity silicone oil for reduced particles, minimal extractabl...

In close cooperation with leading pharmaceuticals companies, Gerresheimer Medical Systems has been developing and producing powder inhalers, capsule inhalers and nebulizers for the treatment of respiratory illnesses like asthma, COPD (Chronic Obstructive Pulmonary Disease) and cystic fibrosis for m...

In the pen injector product segment, our core competence lies both in high quality, reusable pen injectors and in economically produced disposable pens, including glass cartridges. Our many years of experience in the segment of „lancing devices and lancets" is especially advantageous here. We activel...

Make the fill & finish process up to 50% more efficient with vials with a Velocity® coating. A major problem in the fill & finish process of conventional borosilicate glass vials is the friction caused by glass-to-glass and glass-to-metal contacts. Frictional resistance reduces the t...

Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class drugs. 

Gerresheimer Primary Packaging Plastics specializesin the widely varied spectrum of pharmaceuticalplastic packaging within solid, liquid andophthalmic applications, plastic vials and plasticbottles for personal care.

Holger Krenz will be speaking at CPHI Milan about Gerresheimer’s platform solutions for primary packaging and drug delivery systems. His presentation will focus on the product benefits of the Gx Elite performance level which are the ideal packaging components for reliable functionality of drug delivery systems.

Ensure highest product quality and lowest cosmetic defects Accelerate drug development by most comprehensive data packages Create tailored system options with state-of-the-art technologies and components Offer best fit for demanding drug formulations by addressing bio-pharmaceutical requirements

"As a solution provider with a unique & dedicated product portfolio​, Gerresheimer is continuously exploring options to better accommodate their customers along the drug development and drug LCM journey. With its newly installed product platforms, Gerresheimer will be combining outstanding quality levels with specific product requirements in dedicated application fields and disease areas. From dental care over hematology, vaccines, diabetes and metabolism disorders into complex and more demanding areas such as Cell Gene Therapy, ophthalmology and oncology ... Gerresheimer will be able to support even better in finding the best containment solution for their specific application. Picking one example, we'll elaborate on our offering in the ophthalmology field ..."

How can device and packaging innovation influence patient ability and motivation to use their treatment?" With examples from research of how patients learn and become motivated, and how industry can use these processes to influence patient outcomes. Patients learn through a mixture of stimuli and learning processes, these stimuli can be adopted into device design and packaging to enhance the patient's feelings about their medication. Presently many patients using complex devices, like inhalers, make critical errors which entails repeated re-training. This presentation looks at innovative ways of embedding learning, that could be adopted by future device and packaging design.

What are blister packs, and why are they so important? How have they changed over the years, and where are they heading? This presentation will consider a history of how blister packs have benefitted the supply of medicines to patients worldwide, and how they are continuing to evolve within an increasingly sustainable landscape.

Wearables can take different shapes and sizes and are revolutionizing the way we monitor, treat, and manage health conditions. In this short deep dive, we will look at innovative wearable technologies and how they enable data collection and analysis, patient centric care, personalized medicine and more.

Overcoming challenges when developing subcutaneous drug delivery devices that empower patient self-administration. The trend in parenteral patient therapy has been moving towards the home-care setting for some time as it empowers patient independence. However, home administration brings additional requirements when developing a delivery device, and these are constantly evolving. Patient safety is always paramount, but usability is another critical factor, as well as sustainability and connectivity to support patient adherence. The challenge is to design a device to meet as many requirements as possible that can be ready on the market within 4-8 years. In this presentation we will discuss Gerresheimer’s mission of “innovating for a better life” and how we apply this when developing solutions that respond to the needs of patients, our pharmaceutical industry customers, and the environment, today and into the future.

The talk explores the current integration of digital health in drug delivery and various opportunities that it presents. Delving into the landscape of drug delivery, we examine the rise of connected devices, emphasizing the delicate balance between technology and compassionate care. This session also addresses real-world challenges like adoption, satisfaction, regulatory, and security considerations. Be part of the conversation on overcoming these challenges.

From sight, touch, taste, and smell to hearing, the five senses allow the body to take everything in. Research shows that the more senses are used, the better the memory is gathered, and the process enhanced. How does this theory apply to device development, design conception, and patient experience?